After the first closing of a Series B round Wednesday, Themis Bioscience will have an infusion of €7 million ($7.9 million) to work with as it ushers its Chikungunya fever vaccine into Phase II and welcomes a new chairman and two new board members.
Themis Bioscience and the Institut Pasteur have good news to report from a Phase I trial of their Chikungunya fever vaccine candidate. And the pair thinks its successful results just might lead to advances in other diseases, too.
With recent outbreaks in the Caribbean and the Pacific, the U.S. Centers for Disease Control and Prevention is concerned that the number of chikungunya cases among travelers will continue to rise. But results from an early-stage clinical trial point to a promising vaccine that may be able to prevent transmission of the disease.
Chikungunya fever is a dangerous tropical virus that has recently surfaced in the U.S. after erupting in the Caribbean. But Austria-based Themis Bioscience may eventually have a way to combat it, new data suggest.
Chikungunya and Japanese encephalitis virus (JEV) are both mosquito-borne viruses, and Indian Immunologicals Limited is working on what could be the world's first chikungunya vaccine, as well as...
With the help of a four-year, $3 million grant from the National Institute of Allergy and Infectious Diseases, Inviragen and the University of Texas Medical Branch (UTMB) are furthering development